Business News • PR NewsWire • Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia

Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia

Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia

SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced...

View More : https://www.prnewswire.com:443/news-releases/everest-medicines-announces-approval-of-clinical-trial-application-by-china...

Releted News by prnewswire

Launch der digitalen Physiotherapie-App von Exakt Health -- zertifiziert als Medizinprodukt

Acclaimed Japanese Artist Haroshi Re-Imagines His Most Iconic Pieces With First-Ever NFT Collection On LGND.art

Discovering Mysteries : lancement de la nouvelle saison du documentaire sur la nature de Hainan

Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia

CleanEquity Monaco 2021 - Prêmios de Inovação em Tecnologia Sustentável

CleanEquity Monaco 2021 - Innovationspreise für nachhaltige Technologien

CleanEquity Monaco 2021 - Cérémonie des Sustainable Technology Innovation Awards